Review Rheumatoid Arthritis: Terapi Farmakologi, Potensi Kurkumin dan Analognya, serta  Pengembangan Sistem Nanopartikel

Lutfi Chabib; Zullies Ikawati; Ronny Martien; Hilda Ismail

doi:10.20527/jps.v3i1.5830

Review Rheumatoid Arthritis: Terapi Farmakologi, Potensi Kurkumin dan Analognya, serta Pengembangan Sistem Nanopartikel

Lutfi Chabib, Zullies Ikawati, Ronny Martien, Hilda Ismail

Abstract

ABSTRAK

Rheumatoid arthritis (RA) adalah penyakit autoimun yang menyebabkan peradangan kronis pada sendi. Penatalaksanaan RA harus agresif dan sedini mungkin sehingga mampu meningkatkan hasil jangka pendek maupun panjang penderita. Rheumatoid arthritis akibat reaksi autoimun dalam jaringan sinovial yang melibatkan proses fagositosis. Tujuan dari pengobatan rheumatoid arthritis tidak hanya mengontrol gejala penyakit, tetapi juga penekanan aktivitas penyakit untuk mencegah kerusakan permanen. Penderita RA memulai pengobatan mereka dengan DMARDs (Disease Modifying Anti-Rheumatic Drugs) seperti metotreksat, sulfasalazin dan leflunomid. Alternatif pengobatan yang dapat dijadikan salah satu pilihan dalam penanganan RA yaitu senyawa kurkumin dan analognya. Sistem nanopartikel mampu meningkatan efektifitas dalam pengobatan terutama keadaan RA.

Kata kunci : rheumatoid arthritis, Disease Modifying Anti-Rheumatic Drugs, kurkumin, nanopartikel.

ABSTRACT

Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Management of RA must be aggressive and as early as possible so as to increase the yield of short and long term patients. Rheumatoid arthritis due to an autoimmune reaction in the synovial tissue that involves the process of phagocytosis. The purpose of the treatment of rheumatoid arthritis not only control the symptoms of the disease, but also suppressed disease activity to prevent permanent damage. RA patients begin their treatment with DMARDs (Disease Modifying Anti-Rheumatic Drugs) such as methotrexate, sulfasalazine and leflunomid. Alternative treatments that can be used as an option in the treatment of RA are compounds curcumin and its analogs. Nanoparticle systems is able to increase the effectiveness in the treatment of RA, especially state.

Keywords: rheumatoid arthritis, Disease Modifying Anti-Rheumatic Drugs, curcumin, nanoparticles.

Keywords

rheumatoid arthritis, Disease Modifying Anti-Rheumatic Drugs, curcumin, nanoparticles.

Full Text:

PDF

References

Aggarwal, B., and Harikumar, K., 2009, Potential Therapeutic Effects of Curcumin, the Anti-inflammatory Agent, Against Neurodegenerative, Cardiovascular, Pulmonary, Metabolic, Autoimmune and Neoplastic Diseases, Int J Biochem Cell Biol. 2009 ; 41(1): 40–59

Aletaha D, Neogi, Silman J, Funovits, Felson T. 2010. Rhematoid Arthritis Collaborative Initiative. Arthritis Rheum. 62: 2569 – 2581

Alldredge, B.K., Corelli, R.L, Ernst, M.E, Guglielmo, B.J, Jacobson, P.A, & Kradjan, W.A. 2013, Koda-Kimble & Young’s Applied Therapeutics The Clinical Use of Drugs. Lippincott Williams & Wilkins Pennsylvania, United States of America.

American College of Rheumatology Subcommittee Reumatoid Arthritis. 2012. Guidelines for the Management of Rematoid Arthritis. 46: 328-46

Arthritis Foundation, 2015, Arthritis Foundation Scientific Strategy 2015-2020, http://www.arthritis.org /Documents/arthritis-foundation-scientific-strategy.pdf

Brooke MP. 2014. Rheumalology. Med J Australia.160: 374-377.

Choy, E., 2012, Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis, Rheumatology, 2012 ;51:v3-v11. doi:10.1093 /rheumatology/kes113

Darmawan J.1988. Rheumatic condition in the northern part of Central Java. An epidemiological survey. 97-111.

DiPiro, Robert L. Talbert, Gary, C. Yee, Gary, R. Matzke, Barbara G. Wells, Michael, P. 2010. Pharmacotherapy : A Pathophysiologic Approach. The Mc. Graw Hill Company. USA.

Gupta, S., Patchva, S., Aggarwal, B., 2012, Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials, The AAPS Journal, Vol. 15, No. 1.

Ikawati, Z., Yuniarti, N., Marnono, A., 2014, Acute Toxicity and Suppressive Effects of a Curcumin Analogue Gamavuton-0 (Gvt-0) On CFA-Induced Arthritis in rats, Journal of Applied Pharmaceutical Science, Vol. 4 (11), pp. 019-023.

Innes I.B., Jacobs J.W.G, Woodnurn J, van Laar J.M. Treatment of Rematoid Arthritis 2009. Dalam: Bijlsma JWJ, Buermester GR, da Silva JAP. Eular Coompedium on Rheumatic Diseases. London. 20: 81-91.

Kim J. M & Weian MH. 2007. When does Rhematoid Artritis Begin and Why Do We Need to Know ?. Arthtrits Rheum. 23: 143-156.

Kremer J.M., Alarcon GS, Lightfoot RW. 1994. Methotrexate for Rematoid Arthritis: Suggested Guidelines for Monitoring Liver Toxicity. Arthritis Rheum 37:316-328

Mohanraj, V.J., and Y. Chen. 2006. Nanoparticles-A Review. Tropical Journal of Pharmaceutical Research 5 (1): 561-573.

Muchid A. 2006. Pharmaceutical Care untuk Pasien Penyakit Arthiritis Rematik. Izkafiz. Direkloral Bina Farmasi Komunitas dan Klinik, Ditjen Bina Kefarmasian dan Alat Kesehatan, Jakarta.

Nainggolan, O. 2009. Prevalensi dan Determinan Penyakit Rheumatik di Indonesia. Majalah Kedokteran Indonesia 59: 587-594.

Nikolas, S. 2012. Fatigue in Rheumatoid Arthritis: from Patient Experience to Measurement. Thesis, University of Twente.

Pham, C., 2011, Nanotherapeutic approaches for the treatment of rheumatoid arthritis, Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 ; 3(6): 607–619

Schwinghammer, T.L., & Koehler, J.M. 2009. Pharmacotherapy Casebook : A Patient-Focused Approach. The Mc. Graw Hill Company. USA.

Singh, J., Saag, K., Bridges, L., Aki, E., Bannuru, R., 2015, 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, Arthritis Care & Research, DOI 10.1002/acr.22783, VC 2015, American College of Rheumatology.

Sokka T, B. Abelson, & T. Pincus. 2008. Mortality in Rematoid Arthitis. Clin Exp Rheumatol. 26: 35-36

Tobon G.J., P. Youinou, A. Saraux. 2010, The Environment, Geo-Epidemiology, and Autoimmune Disease: Rematoid arthritis. J Autoimmun 35: 10-4

Patel J, Patel A, Raval M, and Sheth N, 2011, Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan, J Adv Pharm Techno Res, 2(1): 9-16

Perhimpunan Rematologi Indonesia, 2014. Diagnosis dan Pengelolaan Artritis Reumatoid. Perhimpunan Reumaologi Indonesia, Bandung.

Petri M. 2007. Hopkins Lupus Pregnancy Centre: Ten Key Issues in Management. Rheum Dis Clin North Am. 33: 227-34

Saag K.G., Teng G.G, Patkar N.M, Anuntiyo J, Finney C, & Curtis. 2008. American College of Rheumatology Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rematoid Arthritis. Arthritis Rheum. 59: 762-784.

Smeltzer, Suzanne. dan Bare, Brenda, 2002. Buku Ajar Keperawatan Medikal Bedah Brunner dan Suddarth Ed.8. EGC, Jakarta.

Villar, A. M., Naveros, B. C., Campmany, A. C., Trenchs, M. A., Rocabert, C. B. & bellowa, L. H. 2012. Design and optimization of self nanoemulsifying drug delivery systems (SNEDDs) for enhanced dissolution of gemfibrozil. Int J Pharm.

Yazici, Y & Simsek I. 2005. Traetment Options for Rhematoid Arthritis Beyond TNF-Alpha Inhibitors. Expert Rev Clin Phamrcol. 3: 663-666.

Yazici Y., T. Sokka, H. Kautiainen, Swearingen, I. Kulman, Pincus. 2005. Longterm Safety of Methotrexate in Routine Clinical Care: Discontinuation Is Unusual and Rarely Due to Laboratory Abnormalities. Ann Rheum Dis. 64: 207-211

DOI: http://dx.doi.org/10.20527/jps.v3i1.5830